Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 54Active not recruiting 15Terminated 11Withdrawn 6Recruiting 4Unknown 3Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 20daratumumab 17Bortezomib 12Lenalidomide 11pomalidomide 8Cyclophosphamide 8Calcium Dobesilate 7belantamab mafodotin 5isatuximab 4fludarabine 4carfilzomib 4Melphalan 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Specimen Handling 3Biopsy 3tocilizumab 2iberdomide 2Stem Cell Transplantation 2Maintenance 2Injections 2Immunotherapy, Adoptive 2Hyaluronoglucosaminidase 2Fluorodeoxyglucose F18 2Exercise Therapy 2Drug Therapy 2CT103A chimeric antigen receptor 2zanubrutinib 1trametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × ixazomib × Plasma cell × Clear all
NCT06744894 2024-12-20

SIL as Maintenance Therapy in Multiple Myeloma

Navy General Hospital, Beijing

Phase 2 Not yet recruiting
50 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡